Drugs / Vantictumab
Vantictumab
also known as
OMP-18R5
Monoclonal antibody targets FZD1, FZD2, FZD5, FZD7, FZD8 via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02005315 | Sep 2013 → Oct 2017 | malignant pancreatic neoplasm | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01957007 | Sep 2013 → Dec 2016 | cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01973309 | Sep 2013 → Jun 2017 | breast cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01345201 | May 2011 → May 2014 | cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | Ashibio Inc | Results āshibio Reports Promising Preclinical Data for Two First-in-Class Antibodies Targeting Debilitating Bone Disorders at ASBMR Meeting ashibio.com ↗
The data we presented at ASBMR highlight the therapeutic potential of our first-in-class investigative antibodies vantictumab and andecaliximab in disease-relevant mouse models |
All press releases naming this drug 2 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vantictumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01973309 ↗ |
| Known as | OMP-18R5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01345201 ↗ |
| Action | Inhibit | “Frizzled-1 antagonist” CHEMBL2364652 ↗4“Frizzled-2 antagonist” CHEMBL2364652 ↗ “Frizzled-8 antagonist” CHEMBL2364652 ↗ “Frizzled-7 antagonist” CHEMBL2364652 ↗ “Frizzled-5 antagonist” CHEMBL2364652 ↗ |
| Modality | Monoclonal antibody | “Vantictumab is a monoclonal antibody” PMID 32803633 ↗ Aug 2020 |
| Route | Intravenous | “intravenous (IV) infusions of OMP-18R5” NCT01345201 ↗ |
| Target | FZD1 | “Frizzled-1 antagonist” CHEMBL2364652 ↗ |
| Target | FZD2 | “Frizzled-2 antagonist” CHEMBL2364652 ↗ |
| Target | FZD5 | “Frizzled-5 antagonist” CHEMBL2364652 ↗ |
| Target | FZD7 | “Frizzled-7 antagonist” CHEMBL2364652 ↗ |
| Target | FZD8 | “Frizzled-8 antagonist” CHEMBL2364652 ↗ |